Interviews

At the Greater Philadelphia Business Coalition on Health 2023 Wellness Summit, Seun Ross, PhD, explains the business case for achieving health equity.

Meredith McKean, MD, MPH, the associate director of the Sarah Cannon Research Institute's Melanoma and Skin Cancer Research Program at Tennessee Oncology, discussed new melanoma studies and treatment developments.

Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, co-presented “Value-Based Care: What Is It and Why Should We Care?” at our most recent Institute for Value-Based Medicine® event with the Zangmeister Cancer Center of Columbus, Ohio, on September 14.

If clinicians empower individuals by giving them the appropriate tools and education to promote brain health, it can make a big difference, said Alvaro Pascual-Leone, MD, PhD.

Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care, spoke at our recent Institute for Value-Based Medicine® event held with Zangmeister Cancer Center. Here, she addresses the importance of value-based care within the primary care space.

The UPMC Health Plan Neighborhood Center, which first opened its doors in December 2022, offers a wide array of services to support plan members and others living in the community.

Patients now have higher expectations of us health care professionals, and we have to meet those expectations, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, explained what testing needs to be done to identify the best treatment for patients with lung cancer.

We are in the midst of a transformative time in oncology that could also be a little scary if you are not prepared, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute, explains how findings from the HEART-FID trial add to the value of ferric carboxymaltose injection.

Michael Petrosky, MD, of the Allegheny Health Network, discusses how monoclonal antibodies will help in the prevention of respiratory syncytial virus (RSV) in infants.

In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.

At the Greater Philadelphia Business Coalition on Health 2023 Wellness Summit, Vikki Walton, MBA, addresses the role employers have in health equity.

Susan Spratt, MD, senior medical director, Duke Population Health Management Office, breaks down the the prevalence of diabetes in the United States and discusses current diabetes initiatives at Duke Health.

Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

"Even though awareness was increasing, it wasn't translating into action," Taylor-Desir explains. "We know from our experience as physicians, that physical health and mental health are tied."

"We really have to work on our implicit bias, acknowledging it, understanding it, and doing the work to try to change it," Veronica Gillispie-Bell, MD, MAS, says.

Despite not reaching statistical significance, findings from DICTATE-AHF show early dapagliflozin improved decongestion and led to earlier hospital discharge for patients with acute decompensated heart failure, explained Zachary Cox, PharmD, professor at Lipscomb University College of Pharmacy.

A recent CDC study revealed that reports of mistreatment and discrimination during maternity care were high among Black, Hispanic, and multiracial respondents.

Michael Petrosky, MD, of Allegheny Health Network, spoke about the difference between vaccines and monoclonal antibodies and how they can affect treatment in respiratory syncytial virus (RSV).

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy at Emory Winship Cancer Institute, discusses treatment options available to patients with rare diseases, as well as the challenges these patients and their pharmacists face in accessing these treatments.

Carmen Solórzano, MD, FACS, of Vanderbilt University Medical Center (VUMC), discusss how VUMC uses technology to advance cancer treatments and her current research.

Specialty pharmacy is a big area of growth, with opportunity for patients, and specialty pharmacists can help payers and insurers ensure that patients get the full value of oncology medications, noted Andre Harvin, PharmD, MS, MBA, chief pharmacy officer, Oncology Services, Cone Health Cancer Centers.

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.

The consortium involved in the newborn genomic sequencing initiative consists of a diverse and growing selection of stakeholders.

Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discussed improvements in lung cancer outcomes due to new screenings and therapies.

In hemophilia cases where there is uncertainty, especially when your factor level is near the 50% cutoff, genetic testing becomes important, Ragni says.

A patient-centered approach on top of a multifactorial approach will help patients adhere to lifestyle modifications, said Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany.

After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.